NeoLAB™ Solid Tumor Monitor

Innovative, non-invasive, cell-free circulating tumor DNA analysis

Minimally-invasive disease monitoring is becoming an increasingly urgent priority in precision medicine. NeoGenomics offers the NeoLAB Solid Tumor Monitor to enable patients with metastatic solid tumor cancers to avoid repeat biopsies and yet still benefit from an assessment of the current mutation profile of their tumor. This liquid biopsy test analyzes cell-free circulating tumor DNA (ctDNA) in the plasma from a small sample of peripheral blood.

Testing indications:

  • Monitor therapy response and molecular resistance
  • Reveal emergence of new and potentially targetable clones
  • Detect minimal residual disease
  • Predict relapse

Applies to patients with:

  • Any type of solid tumor
  • Metastatic disease
  • FFPE solid tumor sample available for one-time baseline testing

Advantages of monitoring with NeoLAB Solid Tumor

  • Testing assesses the current mutation profile rather than historical data from an archived sample
  • Issues of intra- and intertumor heterogeneity and sampling bias do not apply to circulating tumor DNA
  • It creates opportunity for detection of low-level clones and clonal evolution
  • Monitoring can be more frequent and is more flexible with a simple blood draw
  • Quantitative results allow observation of trends of increase or decrease in the abnormal population

Genes tested

ABL1
AKT1
ALK
APC
ATM
BRAF
CDH1
CDKN2A
CSF1R
CTNNB1
EGFR
ERBB2

ERBB4
FBXW7
FGFR1
FGFR2
FGFR3
FLT3
GNA11
GNAQ
GNAS
HNF1A 
HRAS 
IDH1

JAK2
JAK3
KDR
KIT
KRAS
MET
MLH1
MPL
NOTCH1
NPM1
NRAS
PDGFRA  

PIK3CA
PTEN
PTPN11
RB1
RET
SMAD4
SMARCB1
SMO
SRC
STK11
TP53
VHL

Testing requirements

  1. Patient has metastatic disease at time of blood draw
  2. Patient’s tumor has previously tested positive for mutation(s) with one of the other solid tumor tests at NeoGenomics
  3. NeoTYPE™ Precision Profile is run concurrently with the blood sample for monitoring if prior solid tumor testing not performed

Getting Started